
TAT-Gap19
CAS No. 1507930-54-2
TAT-Gap19( —— )
Catalog No. M30790 CAS No. 1507930-54-2
Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penetrant.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTAT-Gap19
-
NoteResearch use only, not for human use.
-
Brief DescriptionCx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penetrant.
-
DescriptionCx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penetrant.
-
In Vitro——
-
In VivoA single injection of TAT-Gap19 (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice. TAT-Gap19 (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks.
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetGap Junction Protein
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1507930-54-2
-
Formula Weight2703.28
-
Molecular FormulaC119H212N46O26
-
Purity>98% (HPLC)
-
Solubilitywater:1 mg/mL
-
SMILES[H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Abudara et al (2014) The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front.Cell.Neurosci. 8 1 PMID:
molnova catalog



related products
-
GAP-134 hydrochlorid...
A potent, orally active gap-junction modifier; prevents significantly conduction velocity slowing at 10 nM compared with vehicle.
-
Carbenoxolone disodi...
An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.
-
GAP-134
A potent, orally active gap-junction modifier; prevents significantly conduction velocity slowing at 10 nM compared with vehicle.